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Abstract Content: Background: There is an immense interest in using Whole Blood (WB) transfusion for early
resuscitation of trauma patients with major bleeding in the pre-hospital setting. The shelf-life of WB component (21-35
days depending on jurisdiction) was established decades ago, primarily based on the viability of red cells. This study
aimed to determine the platelet function of leucocyte-depleted WB (LD-WB) over storage in order to re-establish the shelf
life.
Methods: LD-WB was prepared using a platelet-sparing LD filter (Terumo WB-SP Imuflex). LD-WB was held at 2 – 6 ºC
alongside comparator arms consisting of: A) UK standard pooled buffy coat platelets stored at 20 - 24 °C (RT-PLTS) B)
pooled platelets held at 2 - 6 °C (COLD PLTS) and C) platelet rich plasma (PRP) produced using the Terumo Imuflex WB-
SP kit, for 21 days. A series of in vitro assays were assessed.
Results: There were fundamental changes in the platelet function of LD-WB over storage at 2 – 6 °C for 21 days. Platelet
count was retained to a mean of 57 ± 14 % of starting number at day 21 in 80 % of LD-WB components compared with
97 ± 2 % at end of shelf  life (day 7) in RT-PLTS. Over time the platelets in LD-WB become more activated, as seen in
increased CD62P expression (Day 1 - 7 ± 3.7 % vs. Day 21 - 59 ± 17.1 %) and annexin V binding (Day 1 – 2 ± 0.2 % vs.
Day 21 – 21 ± 15.1 %). For comparison, 18.6 ± 6 % of platelets in RT-PLTS demonstrated CD62P expression at day 7
whilst  Annexin V binding in RT-PLTS at  day 7 was 2.6 ± 0.5 %. LD-WB demonstrated decreased response to agonists
over time (CD62P expression with ADP: (Day 1 - 73 ± 9 %, Day 21: 13 ± 8 %), TRAP-6: (Day 1 - 80 ± 6 %, Day 21 – 13
± 8 %), CRP-XL: (Day 1 - 64 ± 15 %, Day 21 – 11 ± 12 %).  From day 12 onwards, LD-WB showed very little ability to
aggregate in response to ADP and TRAP-6. Platelet-derived microparticles increased steadily throughout storage, which
corresponded with increased potential to promote thrombin generation (Day 1 – 72 ± 5.7 s to clot vs. Day 21 – 38 ± 3.5 s
to clot) in LD-WB. Metabolism was higher in RT-PLTS than cold-stored components.
Conclusion:  During  storage  of  LD-WB,  there  is  a  substantial  loss  of  platelet  count,  coupled  with  progressive  loss  of
aggregatory response, and increased activation. These data, along with previously published work to understand red cell
function  and plasma quality  in  LD-WB in  vitro  and international  experience,  were  used to  recommend a  shelf  life  of  14
days for LD-WB in the UK. This work is part of ongoing collaborative efforts to establish the clinical need and feasibility of
WB in the treatment of major haemorrhage, particularly in the pre-hospital environment.
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